Brivaracetam Intravenous and Sustiva

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of brivaracetam, which is partially metabolized by the isoenzyme. Blood level of brivaracetam is increased by 22% or 42%, respectively, in human subjects possessing genetic variations in CYP450 2C19 with one or both mutated alleles, while production of the hydroxy metabolite is decreased by 2-fold or 10-fold, respectively. The risk of a clinically relevant CYP450 2C19-mediated interaction is considered to be low according to the manufacturer.

Brivaracetam Intravenous

Generic Name: brivaracetam

Brand name: Briviact

Synonyms: Brivaracetam (oral/injection), Brivaracetam

What is Brivaracetam Intravenous?

Sustiva

Generic Name: efavirenz

Brand name: Sustiva

Synonyms: n.a.

What is Sustiva?